Canada · Delayed Price · Currency is CAD Pharmala Biotech Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted a focused strategy on MDMA drug development and supply, strong customer retention through reliability and regulatory compliance, and a data-driven business model leveraging clinical partnerships. Expansion in Australia and New Zealand, asset monetization, and an AI-driven IP platform were also emphasized.
Fiscal Year 2025
-
MDMA therapy achieves a 70% PTSD remission rate in three months, with expanding global distribution and insurance reimbursement. Novel analogs with improved safety are in development, supported by strong IP, regulatory barriers, and partnerships with top research institutions.
-
Revenue nearly doubled year-over-year, driven by MDMA sales and increased customer deposits. Distribution resumed with a new partner, and over CAD 1.5 million was raised to strengthen the cash position. U.S. market growth and new funding for clinical trials are key near-term priorities.